Viatris Analyst Ratings
BenzingaMar 28 12:21 ET
Teva Upgraded at J.P. Morgan on Upcoming Catalysts
Seeking AlphaMar 8 10:21 ET
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $11
BenzingaNov 22, 2023 12:57 ET
Viatris Analyst Ratings
BenzingaNov 22, 2023 12:52 ET
Viatris Downgraded at BofA Citing Business Transition
Seeking AlphaOct 23, 2023 13:41 ET
B of A Securities Downgrades Viatris to Underperform, Announces $9 Price Target
BenzingaOct 23, 2023 07:21 ET
Viatris Analyst Ratings
BenzingaOct 23, 2023 07:20 ET
Piper Sandler Sticks to Their Hold Rating for Viatris (VTRS)
TipRanksAug 8, 2023 08:55 ET
Barclays Downgrades Viatris to Underweight, Announces $11 Price Target
BenzingaJun 23, 2023 05:47 ET
Barclays Downgrades Viatris to Equal-Weight, Lowers Price Target to $11
BenzingaApr 25, 2023 09:05 ET
Barclays Downgrades Viatris to Equal-Weight, Announces $11 Price Target
BenzingaApr 24, 2023 07:01 ET
Barclays Maintains Overweight on Viatris, Raises Price Target to $16
BenzingaFeb 28, 2023 09:30 ET
Barclays Adjusts Price Target on Viatris to $16 From $15, Keeps Overweight Rating
MT NewswiresFeb 28, 2023 07:28 ET
BMO Capital Downgrades Viatris to Market Perform, Lowers Price Target to $14
Benzinga Real-time NewsFeb 17, 2023 05:13 ET
Barclays Adjusts Price Target on Viatris to $15 From $16, Maintains Overweight Rating
MT NewswiresFeb 1, 2023 11:19 ET
Jefferies Upgrades Viatris to Buy, Raises Price Target to $15
Benzinga Real-time NewsJan 27, 2023 06:26 ET
JP Morgan Maintains Neutral on Viatris, Raises Price Target to $14
Benzinga Real-time NewsNov 15, 2022 12:06 ET
UBS Upgrades Viatris to Neutral From Sell, Adjusts Price Target to $12 From $9
MT NewswiresNov 10, 2022 12:12 ET
Analyst Ratings for Viatris
Benzinga Real-time NewsNov 10, 2022 11:54 ET
UBS Upgrades Viatris to Neutral, Raises Price Target to $12
Benzinga Real-time NewsNov 10, 2022 04:56 ET
No Data
No Data